[The adverse reaction of L-asparaginase and its prevention].
Lai
Yong-hong
YH
Wu
Zi-liang
ZL
Chen
Fu-xiong
FX
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004342:Drug Hypersensitivity / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001215:Asparaginase